Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

Abstract Background Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be si...

Full description

Bibliographic Details
Main Authors: Muhammad Babar Khan, Rosamaria Ruggieri, Eesha Jamil, Nhan L. Tran, Camila Gonzalez, Nancy Mugridge, Steven Gao, Jennifer MacDiarmid, Himanshu Brahmbhatt, Jann N. Sarkaria, John Boockvar, Marc Symons
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Molecular Medicine
Subjects:
Glioblastoma
Temozolomide resistance
MicroRNA delivery
Nanoparticle
Heterogeneity
Online Access:https://doi.org/10.1186/s10020-021-00293-4

Internet

https://doi.org/10.1186/s10020-021-00293-4

Similar Items